Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Back to Journals Journal of Inflammation Research Volume 14 N-Acetylcysteine as Adjuvant Therapy for COVID-19 A Perspective on the Current State of the Evidence Authors Wong KK, Lee SWH , Kua KP Received 24 February 2021 Accepted for publication 26 May 2021 Published 6 July 2021 Volume 2021:14 Pages 29933013 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 6 Editor who approved publication: Professor Ning Quan Kon Ken Wong, 1, 2 Shaun Wen Huey Lee, 3 6 Kok Pim Kua 7 1 Department of Microbiology and Immunology, Hospital Canselor Tuanku Muhriz UKM, Cheras, Kuala Lumpur, Malaysia
You might feel temporarily lethargic as your body adjusts to the drug
By starting at a lower dose and titrating upward based on your individual tolerance and response, personalized therapy minimizes side effects while maximizing metabolic benefits
What we know: The same total amount reaches your bloodstream - Clinical trial data confirmed equivalent overall absorption (AUC and Cmax) across all three sites Yet reported side effect rates differed substantially - Thigh showed roughly half the nausea rate of abdomen despite identical systemic exposure Possible explanations include differences in absorption rate (even if total absorption is equal), local tissue effects at the injection site, or simply statistical variation in a relatively small study
